Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24184982 | 0.91 | ACACB (0.48) | P2RY6MIFALDH1A3KMT2ACA1 | |
| SCHEMBL5796149 | 0.81 | MIF (0.44) | P2RY6MIFALDH1A3KMT2ACA2 | |
| SCHEMBL9111062 | 0.81 | ALDH1A3 (0.53) | ALDH1A3KMT2APARP10POLBGLA | |
| SCHEMBL1588318 | 0.78 | P2RY6 (0.48) | P2RY6MIFKMT2ACA1CA2 | |
| SCHEMBL125543 | 0.78 | ALDH1A3 (0.64) | ALDH1A3KMT2APARP10LMNAGAA | |
| Bitoscanate SCHEMBL157128 | 0.78 | MIF (0.72) | P2RY6MIFKMT2ACA1CA2 | |
| SCHEMBL40681 | 0.77 | MIF (0.53) | P2RY6MIFCA1CA2GAA | |
| SCHEMBL941550 | 0.77 | MIF (0.56) | P2RY6MIFKMT2ACA1CA2 | |
| SCHEMBL11852926 | 0.76 | P2RY6 (0.47) | P2RY6MIFKMT2ACA1CA2 | |
| SCHEMBL6181229 | 0.76 | P2RY6 (0.43) | P2RY6MIFCA1CA2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| US-10442772-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-15 | — | — | US | disclosed |
| EP-3105209-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3105210-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-9957235-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-01 | — | — | US | disclosed |
| US-9951027-B2 | Benzimidazol-2-amines as MIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20170197922-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| US-7662977-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| WO-2009108704-A1 | O-ALKYLATED PI-3 KINASE INHIBITOR PRODRUG COMBINATION | SEMAFORE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SIGNALRX PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-7396828-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1855548-A2 | MOLECULES COMPRISING LINKED ORGANIC MOIETIES AS FLAVOR MODIFIERS FOR COMESTIBLES COMPOSITIONS | Senomyx, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060257543-A1 | Molecules comprising linked organic moieties as flavor modifiers for comestible compositions | SENOMYX, INC. | 2006-11-16 | — | — | US | disclosed |
| WO-2006084184-A2 | MOLECULES COMPRISING LINKED ORGANIC MOIETIES AS FLAVOR MODIFIERS FOR COMESTIBLE COMPOSITIONS | SENOMYX, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2004089925-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SEMAFORE PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040116417-A1 | Thiohydantoins and use thereof for treating diabetes | LABORATOIRES FOURNIER SA (FR) | 2004-06-17 | — | — | US | disclosed |
| CN-1500081-A | Thiohydantonins and use thereof for treating diabetes | ʵ���Ҹ���Ү��˾ | 2004-05-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | P2RY6 1187/4885MIF 3660/4885ALDH1A3 3878/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | P2RY6 1187/4885MIF 3660/4885ALDH1A3 3878/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | P2RY6 1187/4885MIF 3660/4885ALDH1A3 3878/4885 |
| US-10442772-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | HRH1, HRH2, HRH3 | P2RY6 3869/4885MIF 3679/4885ALDH1A3 1907/4885 |
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | PI4KA, PI4KB, PI4K2B | P2RY6 968/4885MIF 1708/4885ALDH1A3 4282/4885 |
| US-20170197922-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | HRH1, HRH2, HRH3 | P2RY6 3887/4885MIF 3655/4885ALDH1A3 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.